Creating Equitable Access

We are a nonprofit pharmaceutical organization working toward a world where all women have access to the medicines they need.
Learn More

Our Mission

To catalyze equitable access to

medicines & devices through

product development, policy advocacy,

and collaboration with U.S. and

global partners.

Our Purpose

All women, regardless of socio-economic status, race, ethnicity, or background deserve access to medicines and the stability it provides in order to support their physical health and wellbeing.
However, current systems have failed to ensure that all women have reliable and equitable access to necessary medicines and quality healthcare. This results in a host of complex, interrelated challenges to access, precluding many women from life-altering medicines.
Despite increases in insurance coverage in the U.S., many women still lack meaningful access to medicine because of high out-of-pocket costs and limitations in the medications that insurers will cover
Nearly 13.9 million women across the U.S. live in poverty. More than 10.3 million women are completely uninsured, and roughly 15 million women rely on Medicaid for health coverage1
Reimbursement for family planning care at publicly funded clinics in the U.S. fails to keep pace with the costs of buying and stocking women’s health products and providing related services
Investment in women’s health research and drug development – including birth control and treatments for common conditions such as uterine fibroids, menopause symptoms, and pelvic pain has been historically limited
In 2019, it is estimated that 218 million women had an unmet need for modern contraception worldwide , with 27% aged 15-24 and 60% living in sub-Saharan Africa and Asia2
Previous slide
Next slide

Our Approach

As a nonprofit pharmaceutical organization focused on women’s health, Medicines360 is committed to developing products that enable more access for women by:

Identifying gaps through research and analysis

Conducting pharmaceutical development to bring new products to market

Engaging in values-aligned strategic collaborations that further our mission

Leveraging philanthropic investment

Our longstanding commitment to addressing unmet needs in healthcare by working alongside stakeholders and providers is also reflected in the work we do through our subsidiary, Curae Pharma360 Inc, which is focused on improving the availability of quality generic drugs and other medicines that are in short supply.

Our Work

Research into unmet needs in women’s health, developing new products, and collaborating with values-driven organizations are central to advancing our work.

As a mission-driven nonprofit pharmaceutical organization, we are passionate about leveraging science to develop effective medicines and devices that close access gaps for women around the world. Our highly skilled team of scientists, regulatory experts, clinicians, and public sector engagement associates are dedicated to not only bringing products to market, but also ensuring that women have equitable access to our products in the U.S. and globally.

Read More

U.S. Accomplishments

Conducted the United States’
largest &

most

diverse
Phase 3 clinical trial ever on a hormonal intrauterine device (IUD)

Made our hormonal IUD available to more than
 1.5 million


women throughout the United States

Served
 2,500
publicly funded clinics throughout the U.S.

Saved the U.S. public healthcare system over an estimated
$166 million

Global Efforts

Medicines360, through its wholly owned subsidiary Impact RH360, is working to make our hormonal IUD available in Africa, South and Southeast Asia, and Central America and the Caribbean under the brand name Avibela™.

AVIBELA can be made available in the 88 countries shown in the map below. AVIBELA is currently registered Kenya, Madagascar, Nigeria, Rwanda, Tanzania, Uganda, and Zambia.

Available
(81 countries)

Registered*
(7 countries)

World map with countries in Africa, South and Southeast Asia, and Central America and the Caribbean highlighted in purple and magenta.

* As of November 2022

For more product information, visit Avibela.com

Healthcare Access is Essential

Medicines360 is committed to helping bridge gaps in women’s health.

To ensure that we’re filling unmet product development needs, we actively conduct research among U.S. women and healthcare providers to understand the evolving experience of accessing healthcare.

Learn More

We have found that: 

77%

of women have experienced at least one challenge accessing women’s health services3

More than
10 million

women are completely uninsured4

Roughly 15 million

women rely on Medicaid for healthcare coverage5
Read the Complete Findings

The Latest News

View All

Stay Informed

Sign up to receive updates about our work focused on improving women’s health.

Medicines360 respects individual privacy and values the confidence of our customers. By submitting the information above, you understand this information will be used in accordance with our Privacy Policy. You further acknowledge that Medicines360 and its business partners may send you relevant information regarding disease education, as well as information on related products or services, and for marketing or other informational purposes. You may opt out of receiving such communications by unsubscribing directly from emails sent to you or sending an email request to the address below. Your choices regarding our use and disclosure of your Personal Information:

We give you many choices regarding our use and disclosure of your Personal Information for marketing purposes.  You may opt out from: 

  • Receiving marketing-related emails from us:  If you no longer want to receive marketing-related emails from us on a going-forward basis, you may opt out of receiving these marketing-related emails by following the instructions included in email communications from us, or contact us at: access@medicines360.org.
  • Our sharing of your Personal Information with affiliates for their marketing purposes:  If you would prefer that we do not share your Personal Information on a going-forward basis with our affiliates for their marketing purposes, you may opt out of this sharing by notifying us sending us a written statement to: Medicines360 Website, 49 Stevenson St | Suite 1100 | San Francisco, CA 94105  USA,  by following the instructions included in email communication you received  from us, or by contacting us at: access@medicines360.org.
  1. Kaiser Family Foundation. Women’s Health Insurance Coverage. Accessed June 2022
  2. The Lancet. Measuring contraceptive method mix, prevalence, and demand satisfied by age and marital status in 204 countries and territories, 1970–2019: a systematic analysis for the Global Burden of Disease Study 2019. Accessed August 2022
  3. Sully EA et al., Adding It Up: Investing in Sexual and Reproductive Health 2019, New York: Guttmacher Institute, 2020, https://www.guttmacher.org/fact-sheet/investing-sexual-and-reproductive-health-low-and-middle-income-countries
  4. AVIBELA is not available in the United States. In the US, our hormonal IUD is marketed under the name LILETTA®.